



Otsuka America Pharmaceutical, Inc.

October 23, 2008

Dear Valued Customer:

Please be advised that on March 7, 2008 Otsuka Pharmaceutical Co., Ltd (OPC) acquired the rights to IV BUSULFEX[®] (busulfan) Injection from PDL BioPharma, Inc. Otsuka America Pharmaceutical, Inc. (OAPI), an US affiliate of OPC, now markets the product for its current indication. The last day that OAPI will ship the PDL NDC will be October 31, 2008. The first day for shipping Otsuka labeled product will be November 03, 2008. Please update your systems to reflect the new NDC number, 59148-070-91, as the OAPI labeler code for ordering IV BUSULFEX[®] on and after November 03, 2008.

<u>Product Description</u>	<u>Previous NDC</u>	<u>New NDC</u>	<u>List Price</u>
IV BUSULFEX [®] , (busulfan) Injection 8 x 10 mL vials (6 mg/mL)	67286-0054-08	59148-070-91	\$5810.24

There is no need to return any product. You may continue to dispense the product with the old NDC. Any expired returns with either NDC for BUSULFEX should be returned following the OAPI Returned Goods Policy dated July 1, 2008.

Please feel free to contact me with any questions.

Sincerely,

A handwritten signature in black ink that reads "Italo Pennella".

Italo Pennella R.Ph.
Associate Director of Trade
Otsuka America Pharmaceutical, Inc.
480-218-1200
italo.pennella@otsuka.com

Please see accompanying FULL PRESCRIBING INFORMATION, including **Boxed WARNING** and Indication for IV BUSULFEX[®].

Otsuka America Pharmaceutical, Inc., 2440 Research Blvd., Rockville, MD 20850